Actively Recruiting
Effect of Percutaneous Coronary Intervention on Clinical Prognosis of Chronic Coronary Artery Occlusion
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-12-27
258
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate whether long-term clinical outcomes improve for patients with coronary chronic total occlusions (CTOs) when treated with successful percutaneous coronary intervention (PCI) compared to optimal medical therapy (OMT). The study includes patients who had CTO lesions treated at the First Affiliated Hospital of Nanjing Medical University between January 2011 and December 2017. Researchers focus on the impact of these treatments on major adverse cardiac cerebrovascular events (MACCE) and all-cause death. Participants were divided into two groups based on the treatment they received: the successful CTO-PCI group and the CTO-OMT group. The PCI group underwent the procedure aimed at reopening blocked coronary arteries, while the OMT group received medications such as aspirin, ACE inhibitors or ARBs, beta blockers, and statins. The study compares these treatment approaches to understand their effects on patient health over time. Throughout the study period, researchers tracked major adverse cardiac cerebrovascular events including cardiac death, recurrent heart attacks, unplanned revascularization procedures, and strokes. They also monitored all-cause death. The study followed patients for outcomes from January 2011 through December 2023, with data collection continuing until September 2025. Participants' health events and survival were carefully recorded to assess the long-term prognosis of each treatment approach.
CONDITIONS
Brief Title
Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with at least one coronary chronic total occlusion (CTO) lesion treated at the hospital between January 2011 and December 2017
You will not qualify if you...
- Patients with ST-segment elevation myocardial infarction (STEMI)
- History of coronary artery bypass grafting (CABG)
- Cardiogenic shock
- Malignant tumor
- Patients referred for PCI based on CTO-related symptoms, evidence of viability, or ischemia in the CTO artery area are considered but may be excluded if criteria are not met or for other reasons stated above in exclusion criteria
- Patients excluded due to CABG surgery before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies depending on treatment received
Participants receive either successful percutaneous coronary intervention (PCI) or optimal medical therapy (OMT) for coronary chronic total occlusion.
1 visit for PCI or ongoing medication management for OMT
Duration - Up to 12 years
Participants are monitored for major adverse cardiac cerebrovascular events and all-cause death over an extended period.
Periodic follow-up visits over several years
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China, 210009
Actively Recruiting
Research Team
M
Mei Wang
L
Lei Jiang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here